Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) just unveiled an announcement.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has scheduled a board meeting for 23 March 2026 to review and approve the annual results for the year ended 31 December 2025 for the company and its subsidiaries. The session will also address other corporate matters, reflecting routine governance and financial disclosure practices for the Hong Kong-listed biopharma group.
Following the board’s approval and release of the 2025 annual results, the company will host a webcast conference call with management on 23 March 2026, accessible via an online link and its investor relations website. The planned webcast underlines Kelun-Biotech’s efforts to engage investors and stakeholders with timely information on its financial performance and operational outlook.
The most recent analyst rating on (HK:6990) stock is a Buy with a HK$545.00 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a Hong Kong-listed biopharmaceutical company focused on developing and commercializing biotechnology-based medicines through its operations in the People’s Republic of China and its subsidiaries. The group’s activities center on innovative drug research, development and related biopharma products for both domestic and international markets.
Average Trading Volume: 556,950
Technical Sentiment Signal: Hold
Current Market Cap: HK$96.45B
For an in-depth examination of 6990 stock, go to TipRanks’ Overview page.